Investigation of the Adverse Events Associated with Bee Venom Pharmacopuncture in Patients Hospitalized in a Korean Hospital: A Retrospective Chart Review Study.
In-Hu BaeWoo-Sang JungSeungwon KwonHan-Gyul LeeSeung-Yeon ChoSeong-Uk ParkSang-Kwan MoonJung-Mi ParkChang-Nam KoKi-Ho ChoPublished in: Toxins (2022)
In bee venom pharmacopuncture (BVP), bee venom isolated from the venom sac of bees is injected into the acupoint or muscle associated with a disease. However, the histamine component in bee venom can cause adverse events; therefore, attention is required for BVP use. This study investigated the frequency, severity and characteristics of patients developing BVP-associated adverse events. The medical records of patients treated with BVP at Kyung Hee University Korean Medicine Hospital between 1 January 2013 and 1 May 2021 were reviewed. The demographic characteristics, disease-related characteristics, treatment-related characteristics and impressions of each patient were analyzed. In this study, >50% of 4821 inpatients were hospitalized for neurological disorders. The mean age of the overall study population was 54.62 ± 16.38 years and 61% were women. The frequency of adverse events was 2.32%. The mean age in the adverse events group was 58.20 ± 16.10 years and 76% were women. Two patients experienced moderate adverse events, with no commonality between these events. Every patient recovered naturally with no sequelae. The results showed that BVP is a relatively safe therapeutic method. However, further studies are needed to determine the frequency of adverse events and identify the causality between baseline characteristics and adverse events.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- healthcare
- prognostic factors
- peritoneal dialysis
- type diabetes
- polycystic ovary syndrome
- skeletal muscle
- pregnant women
- patient reported
- patient reported outcomes
- blood brain barrier
- high intensity
- high resolution
- adipose tissue
- single molecule
- adverse drug
- cerebral ischemia